+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
All Genders
ID06202261

Phase IbII Trial Testing Safety and Effectiveness of TQB2930 Alone or with Chemotherapy for HER2-Positive Recurrent or Metastatic Breast Cancer

Led by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Updated on 2024-03-12

154

Participants Needed

2

Research Sites

43 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of TQB2930 for injection, a HER2 bispecific antibody, given alone or combined with other treatments in patients with recurrent or metastatic breast cancer expressing HER2. This phase IbII trial includes advanced malignancies, focusing on patients with a limited life expectancy and prior treatment failures. The study aims to find the best dose and observe the treatments impact on tumor response and patient survival. The trial has multiple treatment groups. Phase Ib involves dose escalation and expansion of TQB2930 alone or in combination with drugs like paclitaxel albumin-bound, TQB3616 capsule plus fulvestrant, or chemotherapy agents such as capecitabine, vinorelbine, eribulin, or gemcitabine. Dosages and treatment cycles vary TQB2930 is given at 10, 20, or 30 mgkg on weekly or biweekly schedules with cycles lasting 21 or 28 days. Phase II further assesses safety and efficacy using combinations determined from earlier results. Participants undergo regular evaluations including tumor imaging to measure remission rates, blood tests for drug levels and immune response, and monitoring for side effects over periods ranging from months to years. The primary outcomes include maximum tolerated dose, objective remission rate, and recommended phase II dose. Secondary outcomes monitor survival, disease control, adverse events, and drug concentration. The study runs until 2027, with ongoing safety and efficacy assessments throughout.

CONDITIONS

Brief Title

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

Research Team

Q

Qingyuan Zhang, Doctor

X

Xiaohua Zeng, Doctor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here